Sources Healthline: Weight Loss is Often a Losing Battle NIH: Glucagon-like peptide 1 (GLP-1) Cleveland Clinic: GLP-1 Agonists NIH: Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes American Diabetes Association: GLP-1 Receptor in Pancreatic -Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner NIH: GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels NIH: Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function FDA: Concern Over Compounded GLP-1 Drugs FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Medical Disclaimer This information is for educational use only
There is no need to store injection pens in the office fridge or carry sharps containers while on vacation
Clinical trials indicate that the medication is safe for extended use, with most patients experiencing mild to moderate gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation
Tirzepatide produced a mean weight reduction of 20.2% compared to 13.7% with semaglutide a statistically significant 6.5 percentage point difference
Semaglutide medication tells your body to release insulin, so your blood sugar may drop lower than usual, causing sluggishness or fatigue
This section shows No Actions Found if the provider has a clean record
